Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SL-701 |
Trade Name | |
Synonyms | SL 701|SL701 |
Drug Descriptions |
SL-701 is an immunotherapy that stimulates anti-tumor immune responses against tumor expressing IL13 receptor alpha-2, EphrinA2 and Survivin (J Clin Oncol 36, 2018 (suppl; abstr 2058)). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C114496 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + SL-701 | Bevacizumab SL-701 | 0 | 0 |
SL-701 | SL-701 | 0 | 1 |